Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple next-generation sequencing tests per patient.

Traveling Through the Lung Cancer Treatment Paradigm: Taking TKI-Related AEs Into Consideration for NSCLC

March 15th 2023

In this sixth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the consideration of adverse effects related to treatment with TKIs patients in non–small cell lung cancer.

Adjuvant Targeted Therapies Could Continue to Shift the Treatment Paradigm in NSCLC

March 14th 2023

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

Pembrolizumab Plus Chemotherapy Meets OS End Point in Advanced Malignant Pleural Mesothelioma

March 10th 2023

First-line treatment with the combination of pembrolizumab and chemotherapy generated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone in patients with unresectable advanced or metastatic malignant pleural mesothelioma.

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

March 9th 2023

Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.

Adjuvant Osimertinib Elicits OS Improvement in Early-Stage EGFR-Mutated NSCLC

March 9th 2023

Osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo as adjuvant treatment for patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer after complete tumor resection with curative intent.

Traveling Through the Lung Cancer Treatment Paradigm: Oral Etoposide

March 8th 2023

In this fifth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses instances where oral etoposide could be utilized for patients with small cell lung cancer.

FDA Expands Approval for Companion Diagnostic for Cemiplimab in NSCLC

March 7th 2023

The FDA has approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

Dr. Hassan on the Importance of Accurate Molecular Profiling in Lung Cancer

March 3rd 2023

Khaled Hassan, MD, discusses the importance of performing precise molecular profiling in patients with lung cancer and the need to identify individually tailored treatment approaches.

Traveling Through the Lung Cancer Treatment Paradigm: Managing irAEs With Corticosteroids

March 1st 2023

In this fourth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the management of immune-related adverse effects and the goal of mitigating steroid use for patients with lung cancer.

FDA Approval Sought for Neoadjuvant Pembrolizumab/Chemo Plus Adjuvant Pembrolizumab in Resectable Stage II or IIIA/B NSCLC

March 1st 2023

The FDA has accepted a supplemental biologics license application for neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy, followed by adjuvant pembrolizumab monotherapy, for the treatment of patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer.

Pembrolizumab Plus Standard Therapy Falls Short in mCRPC, EGFR-Mutant NSCLC Trials

February 28th 2023

The addition of pembrolizumab to standard therapies failed to improve survival outcomes in patients with metastatic castration-resistant prostate cancer in the KEYNOTE-641 trial and patients with EGFR-mutated non–small cell lung cancer in the KEYNOTE-789 trial.

Dr. Chao on the Study of PD-L1 Inhibitors with NSCLC

February 24th 2023

Yvonne Chao, MD, PhD, discusses the study of various PD-L1 inhibitors in patients with non–small cell lung cancer.

Cemiplimab Plus Chemotherapy Approaches EU Approval for PD-L1+ NSCLC

February 24th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab-rwlc in combination with platinum-based chemotherapy as frontline treatment for adult patients with advanced non–small cell lung cancer with PD-L1 expression of 1% or higher.

Dr. Patil on Unmet Needs With the Use of Immunotherapy in NSCLC

February 23rd 2023

Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.

Overcoming Barriers to TIL Use in Patients With Solid Tumors

February 23rd 2023

Closing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.

TIL Therapy: Lessons Learned and Potential Future Directions in Care

February 23rd 2023

Experts Amod Sarnaik, MD, and Krishna Komanduri, MD, consider lessons learned about TILs and CAR T-cell therapy in hematologic cancers, and how they anticipate TILs fitting into treatment paradigms for solid tumors.

EU Approves Durvalumab/Tremelimumab Combo for Advanced Lung, Liver Cancers

February 22nd 2023

The European Union has approved durvalumab plus tremelimumab-actl for first-line treatment of advanced or unresectable hepatocellular carcinoma and in combination with platinum-based chemotherapy in metastatic non–small cell lung cancer, according to a news release from AstraZeneca.

Traveling Through the Lung Cancer Treatment Paradigm: Taking Advantage of Neoadjuvant Therapy

February 22nd 2023

In this third episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the expanding role of neoadjuvant therapy in non–small cell lung cancer and efforts to better identify patients who can benefit from curative-intent treatment.

Unmet Needs and Future Perspectives in the NSCLC Treatment Landscape

February 21st 2023

Looking to the future, a panel of experts offer closing remarks on promising developments and unmet needs in the treatment of NSCLC.